Recombinant Human IL-7 Protein, Active, Low Endotoxin
Beta LifeScience
SKU/CAT #: BEP-0041
Recombinant Human IL-7 (2 µg/lane) on SDS-PAGE under reducing (R) conditions. The gel was stained using Coomassie® Blue showing a single band at ~17 kDa and purity greater than 98%.
Recombinant Human IL-7 Protein, Active, Low Endotoxin
Beta LifeScience
SKU/CAT #: BEP-0041
Regular price$1,42400
$1,424.00
/
Submit an inquiry or email sales for a custom bulk quote. Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Connect with us via the live chat in the bottom corner to receive immediate assistance.
Product Overview
| Product Name | Recombinant Human IL-7 Protein |
| Target Symbol | IL7 |
| Alternative Names | Interleukin 7, IL7 |
| Accession Number | P13232 |
| Expression System | E.Coli. |
| Molecular Weight | 17.5 kDa (predicted) |
| Sequence | Asp26-His177, with an N-terminal Met |
| Purity | >98% by SDS-PAGE and quantitative densitometry by CoomassiePurity ® Blue staining |
| Activity | Determined by a cell proliferation assay using 2E8 mouse cells. The ED50 for this effect is typically <0.75 ng/mL. |
| Formulation | Lyophilized from sterile PBS with Trehalose, pH 7.4 |
| Endotoxin Level | <0.05 EU per 1 μg of the protein as determined by the LAL method |
| Shipping | Shipped at ambient temperature. |
| Stability & Storage | 12 months from date of receipt at -20°C to -70°C, lyophilized powder. 3 months at -20°C to -70°C under sterile conditions after reconstitution. Avoid repeated freeze-thaw cycles. |
| Reconstitution | Reconstitute at 100 ug/mL in sterile PBS. If desired, 5% Trehalose or 0.1% BSA may be added. |
| Target Function | Interleukin 7 (IL-7) functions in regulating hematopoeitic stem cell differentiation into lymphoid progenitor cells. IL-7 also plays a role in the proliferation and survival of B cells, T cells and NK cells in the lymphoid lineage. This is led to further developments in applying IL-7 in cell culture and manufacturing strategies in cancer immunotherapy approaches, such as adoptive cell therapy (ACT) and chimeric antigen receptor (CAR) T cell therapy. |
| Tissue Specificity | IL-7 is primarily produced by stromal cells in the bone marrow and thymus with expression also reported in lymph nodes, spleen, intestinal goblet cells, keratinocytes, lung epithelium and liver sinusoidal endothelial cells. |
| Cellular Localization | Secreted protein |
| Involvement In Disease | Dysregulation of IL-7 has been implicated in autoimmune diseases (rheumatoid arthritis, multiple sclerosis, Crohn’s disease, ulcerative colitis), aplastic anemia myelodysplastic syndromes, asthma and chronic obstructive pulmonary disease (COPD), Graft-versus-Host Disease (GVHD), and hematological malignancies (acute lymphoblastic leukemia, T cell lymphoma). |
